polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride
GOLYTELY (polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride) by R-Pharm US is osmotic activity [moa]. First approved in 1984.
Drug data last refreshed 13h ago · AI intelligence enriched 18h ago
GOLYTELY is an oral osmotic laxative solution containing polyethylene glycol 3350 and electrolytes (sodium sulfate, sodium bicarbonate, sodium chloride, potassium chloride) approved in 1984. It is used for bowel cleansing prior to colonoscopy, barium enema, or other GI procedures. The drug works via osmotic activity to draw fluid into the bowel, producing a cathartic effect without systemic absorption.
Approaching loss of exclusivity with modest Medicare spending indicates a mature, defensive commercial posture requiring focus on volume retention and cost management.
Osmotic Activity
Osmotic Laxative
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparison of Clenpiq vs Golytely Bowel Preparation
Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely
Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation
Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy
Worked on GOLYTELY at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on GOLYTELY offers limited career growth potential given its mature lifecycle, low clinical pipeline activity, and approaching LOE. Roles on this product are best suited for professionals focused on commercial execution in stable GI markets or seeking transition opportunities into emerging franchises.